Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

John Johnson


  • Executive Chairman at Strongbridge Biopharma Plc (SBBP), 2019-11-18
  • Chief Executive Officer at Melinta Therapeutics Inc. W (MLNT), 2019-07-03
  • Director at Portola Pharmaceuticals Inc (PTLA), 2019-06-17
  • Director at Histogenics Corp (HSGX), 2018-06-19
  • Director at Sucampo Pharmaceuticals Inc. (SCMP), 2018-02-13
  • Director at Aveo Pharmaceuticals Inc (AVEO), 2018-02-05
  • Pres & Chief Executive Officer at Dendreon Corp (DNDN), 2014-07-08
  • Director at Tranzyme Inc (TZYM), 2012-08-09
  • Chief Executive Officer at Savient Pharmaceuticals Inc (SVNT), 2012-01-04
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
CEMP $9.10 10,000 Director 10,000 2014-05-23 Filing
SVNT $2.30 5,000 Officer, Director 270,000 2011-11-21 Filing
SVNT $2.28 10,000 Officer, Director 265,000 2011-11-18 Filing
SVNT $2.36 1,000 Officer, Director 4,000 2011-11-18 Filing
DNDN $6.68 2,500 Director 12,943 2011-11-04 Filing
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
MLNT $5.57 13,000 Officer, Director 37,400 2019-06-27 Filing
SVNT $2.30 17,650 Officer, Director 252,350 2012-01-03 Filing